1. Clinically guided adjustment of sorafenib daily dose is advisable for cirrhotics patients with hepatocellular carcinoma (HCC). (15th February 2015) Authors: Gallusi, G.; De Santis, A.; Iegri, C.; Lupo, M.; Mascolo, A.; Attili, A.F. Journal: Digestive and liver disease Issue: Volume 47(2015)Supplement 1 Page Start: e34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC). (10th February 2016) Authors: Di Costanzo, G.G.; D'Angelo, S.; Zolfino, T.; Lorusso, V.; Montesarchio, V.; de Stefano, G.; Sacco, R.; Attili, A.F.; Benedetti, A.; Sansonno, D.; Giannitrapani, L.; Buonadonna, A.; Giovanis, P.; Cabibbo, G.; De Vita, F.; Carucci, P.; Pirisi, M.; Moscovici, M.; Pisconti, S.; Daniele, B. Journal: Digestive and liver disease Issue: Volume 48(2016)Supplement 1 Page Start: e45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗